Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins
Authors
Keywords
-
Journal
ACS Chemical Biology
Volume 17, Issue 5, Pages 1259-1268
Publisher
American Chemical Society (ACS)
Online
2022-04-28
DOI
10.1021/acschembio.2c00185
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
- (2021) Adam D. Cotton et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
- (2021) Yaxian Zhou et al. ACS Central Science
- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
- (2021) Green Ahn et al. Nature Chemical Biology
- Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
- (2021) Florian Kast et al. Nature Communications
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
- (2020) Wen-Qi Cai et al. Frontiers in Oncology
- Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
- (2020) Colton J. Bracken et al. Nature Chemical Biology
- Expression Atlas update: from tissues to single cells
- (2019) Irene Papatheodorou et al. NUCLEIC ACIDS RESEARCH
- Frizzled Receptors as Potential Therapeutic Targets in Human Cancers
- (2018) Chui-Mian Zeng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
- (2017) Atrish Bagchi et al. MOLECULAR CANCER THERAPEUTICS
- Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
- (2017) Fei Zhang et al. Oncotarget
- The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
- (2016) E. Allen Sickmier et al. PLoS One
- A High Through-put Platform for Recombinant Antibodies to Folded Proteins
- (2015) Michael Hornsby et al. MOLECULAR & CELLULAR PROTEOMICS
- Bispecific T-cell engagers for cancer immunotherapy
- (2014) Amelia M Huehls et al. IMMUNOLOGY AND CELL BIOLOGY
- Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
- (2012) M. Jack Borrok et al. ACS Chemical Biology
- ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner
- (2012) Huai-Xiang Hao et al. NATURE
- Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
- (2010) Curtis A Thorne et al. Nature Chemical Biology
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation
- (2009) A. Talavera et al. CANCER RESEARCH
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFR
- (2009) T. P. J. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
- (2008) Judith Schmiedel et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now